18/07/2019: Pharegis implemented optimized procedures for state registration of pharmaceuticals in Eurasian Economic Union.
20/06/2019: Pharegis updated timelines and practical approaches for Russian and EEU GMP inspection applications and procedures.
03/04/2019: Renewed general monographs of Russian state pharmacopeia XIV ed. have been analyzed.
Global industry news
ACC: Amgen's Repatha cuts cholesterol in rarely studied HIV patients
ACC: Esperion's Nexletol busts cholesterol levels regardless of statin, ezitimibe therapy
ACC: AstraZeneca's Farxiga shows benefit in heart failure patients regardless of prior treatment
+7 495 442 37 85
+7 985 908 58 18
Registration of Medical Drugs in Russia
Registration of Pharmaceuticals in Russia
Registration of Pharmaceutical Dossier Variations in Russia
Registration of Pharmaceuticals in CIS
Clinical Studies in Russia
Clinical Studies for Registration of Pharmaceuticals in Russia
International Phase III Clinical Studies
Phase I, Phase II (IIa, IIb) Clinical Studies
Preclinical Studies in Russia
Preclinical Studies for Registration of Pharmaceuticals in Russia
Preclinical Studies for Registration of Biopharmaceuticals in Russia
In Vitro Preclinical Studies in Russia
Regulatory Consulting in Russia and EEU
Certification of Medical Drugs and Medical Devices in Russia
Registration of Medical Devices in Russia
Russian GMP inspection of pharmaceutical manufacturers
Regulatory Events Russia
Russian Regulatory News
You are here:
Pharegis LLC / ООО "Фареджис"
3-1 Begovaya str. ("NordStar Tower", 31st flr), Moscow, Russia 125284
Legal & postal address:
11A-11 Cherkizovskaya B. str., Moscow, Russia 107392
TAX ID (TIN): 7718278100
+7 495 442 37 85 9am-6pm GMT+3
+ 7 495 442 37 85
+ 7 985 908 58 18
Send an Email
Send a copy to yourself
SHARE THIS BY:
Create an account
Forgot your username?
Forgot your password?
Drugs.com - New Drug Approvals
FDA Approves Zeposia (ozanimod) for Relapsing Forms of Multiple Sclerosis
FDA Approves Epclusa (sofosbuvir/velpatasvir) for Children Ages 6 and Older or Weighing at Least 17 kg with Chronic Hepatitis C Infection
FDA Approves Ofev (nintedanib) as First Treatment for Chronic Fibrosing Interstitial Lung Diseases (ILDs) with a Progressive Phenotype
FDA Approves Isturisa (osilodrostat) for the Treatment of Cushing’s Disease
FDA Approves Durysta (bimatoprost implant) to Lower Intraocular Pressure In Open-Angle Glaucoma or Ocular Hypertension Patients
News and press releases
EMA advises continued use of medicines for hypertension, heart or kidney disease during COVID-19 pandemic, , 27/03/2020
No change to product information for breast cancer medicine Tyverb following re-assessment of data, CHMP, 27/03/2020
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 March 2020, CHMP, 27/03/2020
New gene therapy to treat spinal muscular atrophy, , 27/03/2020
Drugs.com - Clinical Trials
Gilead Sciences Statement on Request to Rescind Remdesivir Orphan Drug Designation
March 25, 2020 -- Gilead has...
Gilead Sciences Statement on Access to Remdesivir Outside of Clinical Trials
March 22, 2020 -- Gilead is...
Johnson & Johnson Announces Collaboration with the Beth Israel Deaconess Medical Center to Accelerate COVID-19 Vaccine Development
NEW BRUNSWICK, N.J., March...
New Clinical Study Data for Gilead’s Investigational HIV-1 Capsid Inhibitor GS-6207 Presented at CROI 2020
PharmaTimes: PharmaTimes Website RSS
COVID-19: UK commits £210m as pharmacist warns Brits not to stockpile Ventolin inhalers
CHMP gives Sanofi positive opinion for Sarclisa
BMJ journal deems opioid dependency implant more favourable than tablets
Takeda, Evox link up to the tune of $882m
EMA accepts Arvelle’s cenobamate MAA
Terms of Service
Sample Non-Disclosure Agreement